Nurix Therapeutics falls after Q3 results miss

Nurix Therapeutics

09/10/2025 21:29

** Shares of drug developer Nurix Therapeutics NRIX.O fall 7.1% to $10.29 in extended trade

** Company posts Q3 revenue of $7.89 million, compared to analysts' estimate of $16.74 million, according to data compiled by LSEG

** Company reports Q3 net loss of $1.03 per share vs estimated net loss of 84 cents per share

** Cash, cash equivalents and marketable securities were $428.8 million as of August 31

** Including session moves, stock down 42.4% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))